Karyopharm Therapeutics (KPTI) Other Non Operating Income (2013 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly Other Non Operating Income came in at $840000.0 in Q4 2025, down 95.76% on a QoQ basis from $19.8 million in Q1 2025.
Karyopharm Therapeutics (KPTI) Other Non Operating Income (2013 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 13 years of Other Non Operating Income data on file, last reported at $840000.0 in Q4 2025.
- Quarterly Other Non Operating Income changed N/A year-over-year to $840000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $20.7 million (down 53.98% YoY) and the FY2025 annual result came in at $840000.0, down 98.12% from the prior year.
- Other Non Operating Income retreated to $840000.0 in Q4 2025, from $19.8 million in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $44.7 million in Q2 2024 to a low of -$478000.0 in Q4 2021.
- A 5-year average of $4.3 million and a median of $16000.0 in 2022 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2023 — Other Non Operating Income tumbled 2638.46% — and 2025, when it jumped 10014.29%.
- Tracing KPTI's Other Non Operating Income over 5 years: stood at -$478000.0 in 2021, then surged by 97.28% to -$13000.0 in 2022, then plunged by 2638.46% to -$356000.0 in 2023, then soared by 12656.74% to $44.7 million in 2024, then slumped by 98.12% to $840000.0 in 2025.
- The last three Other Non Operating Income figures came in at $840000.0 (Q4 2025), $19.8 million (Q1 2025), and $44.7 million (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Karyopharm Therapeutics | 56.72 Mn | 56.72 Mn | 32.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -32.08 Mn |
| Dec 31, 2025 | 840,000.00 |
| Mar 31, 2025 | 19.82 Mn |
| Jun 30, 2024 | 44.70 Mn |
| Mar 31, 2024 | 196,000.00 |
| Dec 31, 2023 | -356,000.00 |
| Sep 30, 2023 | 89,000.00 |
| Mar 31, 2023 | -264,000.00 |
| Dec 31, 2022 | -13,000.00 |
| Sep 30, 2022 | 16,000.00 |
| Jun 30, 2022 | -13,000.00 |
| Mar 31, 2022 | -73,000.00 |
| Dec 31, 2021 | -478,000.00 |
| Sep 30, 2021 | 18,000.00 |
| Jun 30, 2021 | 436,000.00 |
| Mar 31, 2021 | -61,000.00 |
| Dec 31, 2020 | 383,000.00 |
| Sep 30, 2020 | -141,000.00 |
| Jun 30, 2020 | -61,000.00 |
| Mar 31, 2020 | 25,000.00 |